These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 33430081)

  • 1. Drug Repurposing: Dipeptidyl Peptidase IV (DPP4) Inhibitors as Potential Agents to Treat SARS-CoV-2 (2019-nCoV) Infection.
    Rao PPN; Pham AT; Shakeri A; El Shatshat A; Zhao Y; Karuturi RC; Hefny AA
    Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33430081
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COVID-19 and comorbidities: A role for dipeptidyl peptidase 4 (DPP4) in disease severity?
    Bassendine MF; Bridge SH; McCaughan GW; Gorrell MD
    J Diabetes; 2020 Sep; 12(9):649-658. PubMed ID: 32394639
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Action of Dipeptidyl Peptidase-4 Inhibitors on SARS-CoV-2 Main Protease.
    Nar H; Schnapp G; Hucke O; Hardman TC; Klein T
    ChemMedChem; 2021 May; 16(9):1425-1426. PubMed ID: 33348462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
    Kumar Y; Singh H; Patel CN
    J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Virtual screening of approved drugs as potential SARS-CoV-2 main protease inhibitors.
    Jiménez-Alberto A; Ribas-Aparicio RM; Aparicio-Ozores G; Castelán-Vega JA
    Comput Biol Chem; 2020 Oct; 88():107325. PubMed ID: 32623357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In Silico Evaluation of the Effectivity of Approved Protease Inhibitors against the Main Protease of the Novel SARS-CoV-2 Virus.
    Eleftheriou P; Amanatidou D; Petrou A; Geronikaki A
    Molecules; 2020 May; 25(11):. PubMed ID: 32485894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy.
    Goyal B; Goyal D
    ACS Comb Sci; 2020 Jun; 22(6):297-305. PubMed ID: 32402186
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Systematic Search for SARS-CoV-2 Main Protease Inhibitors for Drug Repurposing: Ethacrynic Acid as a Potential Drug.
    Isgrò C; Sardanelli AM; Palese LL
    Viruses; 2021 Jan; 13(1):. PubMed ID: 33451132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evolving geographic diversity in SARS-CoV2 and in silico analysis of replicating enzyme 3CL
    Chitranshi N; Gupta VK; Rajput R; Godinez A; Pushpitha K; Shen T; Mirzaei M; You Y; Basavarajappa D; Gupta V; Graham SL
    J Transl Med; 2020 Jul; 18(1):278. PubMed ID: 32646487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization Rules for SARS-CoV-2 M
    Stoddard SV; Stoddard SD; Oelkers BK; Fitts K; Whalum K; Whalum K; Hemphill AD; Manikonda J; Martinez LM; Riley EG; Roof CM; Sarwar N; Thomas DM; Ulmer E; Wallace FE; Pandey P; Roy S
    Viruses; 2020 Aug; 12(9):. PubMed ID: 32859008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Binding Mechanism and Pharmacology Comparative Analysis of Noscapine for Repurposing against SARS-CoV-2 Protease.
    Kumar N; Sood D; van der Spek PJ; Sharma HS; Chandra R
    J Proteome Res; 2020 Nov; 19(11):4678-4689. PubMed ID: 32786685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
    Froggatt HM; Heaton BE; Heaton NS
    J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of dipeptidyl peptidase-4 inhibitors in patients with diabetes infected with coronavirus-19.
    Chen CF; Chien CH; Yang YP; Chou SJ; Wang ML; Huo TI; Lin CC
    J Chin Med Assoc; 2020 Aug; 83(8):710-711. PubMed ID: 32349031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Repurposing Therapeutics for Potential Treatment of SARS-CoV-2: A Review.
    Santos J; Brierley S; Gandhi MJ; Cohen MA; Moschella PC; Declan ABL
    Viruses; 2020 Jun; 12(7):. PubMed ID: 32629804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural basis of SARS-CoV-2 main protease inhibition by a broad-spectrum anti-coronaviral drug.
    Wang YC; Yang WH; Yang CS; Hou MH; Tsai CL; Chou YZ; Hung MC; Chen Y
    Am J Cancer Res; 2020; 10(8):2535-2545. PubMed ID: 32905393
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A review of candidate therapies for Middle East respiratory syndrome from a molecular perspective.
    Rabaan AA; Alahmed SH; Bazzi AM; Alhani HM
    J Med Microbiol; 2017 Sep; 66(9):1261-1274. PubMed ID: 28855003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Homologous modeling and binding ability analysis of Spike protein after point mutation of severe acute respiratory syndrome coronavirus 2 to receptor proteins and potential antiviral drugs].
    Cao Z; Wang LT; Liu ZM
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Dec; 53(1):150-158. PubMed ID: 33550350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Permissivity of Dipeptidyl Peptidase 4 Orthologs to Middle East Respiratory Syndrome Coronavirus Is Governed by Glycosylation and Other Complex Determinants.
    Peck KM; Scobey T; Swanstrom J; Jensen KL; Burch CL; Baric RS; Heise MT
    J Virol; 2017 Oct; 91(19):. PubMed ID: 28747502
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biochemical screening for SARS-CoV-2 main protease inhibitors.
    Coelho C; Gallo G; Campos CB; Hardy L; Würtele M
    PLoS One; 2020; 15(10):e0240079. PubMed ID: 33022015
    [TBL] [Abstract][Full Text] [Related]  

  • 20. DPP4 and ACE2 in Diabetes and COVID-19: Therapeutic Targets for Cardiovascular Complications?
    Valencia I; Peiró C; Lorenzo Ó; Sánchez-Ferrer CF; Eckel J; Romacho T
    Front Pharmacol; 2020; 11():1161. PubMed ID: 32848769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.